Oramed Pharmaceuticals (NASDAQ:ORMP) Releases Earnings Results

Oramed Pharmaceuticals (NASDAQ:ORMP) issued its earnings results on Thursday. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.04, Zacks reports.

Oramed Pharmaceuticals Stock Performance

Shares of NASDAQ ORMP traded down $0.09 during midday trading on Friday, reaching $2.21. 74,075 shares of the company’s stock were exchanged, compared to its average volume of 157,620. Oramed Pharmaceuticals has a 52-week low of $1.96 and a 52-week high of $3.14. The business’s fifty day moving average price is $2.30 and its two-hundred day moving average price is $2.35. The stock has a market capitalization of $89.09 million, a PE ratio of 20.09 and a beta of 1.61.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered shares of Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, February 19th.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.